Affiliation:
1. State budgetary healthcare institution of the city of Moscow “Moscow city clinical oncological hospital № 1”; Peoples’ Friendship University of Russia
2. Peoples’ Friendship University of Russia
Abstract
Today we can say with confidence that percutaneous coronary intervention is an effective, minimally invasive and safe method of treating coronary heart disease. As always complex problems require necessary solutions. One such challenge is the use of metallic covered stents because the stent frame remains permanently in the artery. The idea to create a bioresorbable scaffold appeared more than 20 years ago, and one of the pioneers was the Absorb scaffold, which was implanted in quantities of more than 150 000. During the existence of this stent, a large number of studies were carried out, strengths and weaknesses were identified and eventually came to the conclusion that it was discontinued, but creating Absorb gave a powerful drive to the invention of new types of scaffolds.
Publisher
The Institute of Internal and Preventive Medicine
Reference27 articles.
1. Serruys P.W., Ormiston J., van Geuns R.J., de Bruyne B., Dudek D., Christiansen E., Chevalier B., Smits P., McClean D., Koolen J., Windecker S., Whitbourn R., Meredith I., Wasungu L., Ediebah D., Veldhof S., Onuma Y. A polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5-year follow-up. J. Am. Coll. Cardiol., 2016; 67: 766–776. doi: 10.1016/j.jacc.2015.11.060
2. Onuma Y., Dudek D., Thuesen L., Webster M., Nieman K., Garcia-Garcia H.M., Ormiston J.A., Serruys P.W. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc. Interv., 2013; 6: 999–1009. doi: 10.1016/j.jcin.2013.05.017
3. Brugaletta S., Radu M.D., Garcia-Garcia H.M., Heo J.H., Farooq V., Girasis C., Geuns R.J., Thuesen L., McClean D., Chevalier B., Windecker S., Koolen J., Rapoza R., Miquel-Hebert K., Ormiston J., Serruys P.W. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis, 2012; 221: 106–112. doi: 10.1016/j.atherosclerosis.2011.12.008
4. Brugaletta S., Heo J.H., Garcia-Garcia H.M., Farooq V., van Geuns R.J., de Bruyne B., Dudek D., Smits P., Koolen J., McClean D., Dorange C., Veldhof S., Rapoza R., Onuma Y., Bruining N., Ormiston J., Serruys P.W. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy? Eur. Heart. J., 2012; 33: 1325–1333. doi: 10.1016/j.amjcard.2012.01.071.
5. Zagorulko A.I., Sidelnikov A.V., Shevchuk I.V., Koledinsky A.G. The efficacy and safety of Absorb BVS bioresorbable scaffolds in treatment of coronary heart disease in patients with diabetes mellitus. Post-Qualifying Medical Education Herald. 2019; 4: 11–14. (In Russ.)